To dope or not to dope: Neuroenhancement with prescription drugs and drugs of abuse among Swiss university students

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Maier, Larissa J ^a   Liechti, Matthias E ^b   Herzig, Fiona ^a   Schaub, Michael P ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; FEMALE; HUMANS; MALE; NOOTROPIC AGENTS; PERFORMANCE-ENHANCING SUBSTANCES; PRESCRIPTION DRUGS; PREVALENCE; SELF MEDICATION; STREET DRUGS; STRESS, PSYCHOLOGICAL; STUDENTS; SWITZERLAND; UNIVERSITIES; YOUNG ADULT;

EID: 84893612668     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077967     Document Type: Article

References (43)

1. Hildt E, Franke AG, Lieb K (2011) Pharmacological neuroenhancement: information and acceptance among students. Nervenheilkunde 30: 833-837.
2. Franke AG, Bonertz C, Christmann M, Huss M, Fellgiebel A, et al. (2011) Nonmedical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry 44: 60-66.
3. Kordt M (2009) DAK Gesundheitsreport 2009. Hamburg.
4. Normann C, Berger M (2008) Neuroenhancement: status quo and perspectives. Eur Arch Psychiatry Clin Neurosci 258 Suppl 5: 110-114.
5. Eckhardt A, Bachmann A, Marti M, Rütsche B, Telser H (2011) Human enhancement. Zürich: vdf Hochschulverlag. doi:10.3218/3404-2.
6. Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, et al. (2008) Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 456: 702-705.
7. Maher B (2008) Poll results: look who's doping. Nature 452: 674-675.
8. Arria AM, Caldeira MS, O'Grady KE, Vincent KB, Johnson BA, et al. (2008) Nonmedical use of prescription stimulants among college students: associations with attention-deficit-hyperactivity disorder and polydrug use. Pharmacotherapy 28: 156-169. (Pubitemid 351206963)
9. Repantis D (2009) Die Wirkung von Psychopharmaka bei Gesunden. In: Wienke A, Eberbach W, Kramer HJ, Janke K, editors. Die Verbesserung des Menschen. Tatsächliche und rechtliche Aspekte der wunscherfüllenden Medizin. Berlin Heidelberg: Springer. pp. 63-68.
10. Quednow BB (2010) Ethics of neuroenhancement: a phantom debate. BioSocieties 5: 153-156.
11. Förstl H (2009) [Neuro-enhancement. Brain doping]. Der Nervenarzt 80: 840-846.
12. Wilens TE, Adler L, Adams J, Sgambati S, Rotrosen J, et al. (2008) Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 47: 21-31.
13. McCabe SE, Knight JR, Teter CJ, Wechsler H (2005) Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 100: 96-106.
14. Middendorff E, Poskowsky J, Isserstedt W (2012) Formen der Stresskompensation und Leistungssteigerung bei Studierenden. Hannover: HIS.
15. Sahakian B, Morein-Zamir S (2007) Professor's little helper. Nature 450: 1157-1159.
16. Kaloyanides KB, McCabe SE, Cranford JA, Teter CJ (2007) Prevalence of illicit use and abuse of prescription stimulants, alcohol, and other drugs among college students: relationship with age at initiation of prescription stimulants. Pharmacotherapy 27: 666-674. (Pubitemid 46700958)
17. DeSantis AD, Webb EM, Noar SM (2008) Illicit use of prescription ADHD medications on a college campus: a multimethodological approach. J American Coll Health 57: 315-324.
18. Sussman S, Pentz MA, Spruijt-Metz D, Miller T (2006) Misuse of "study drugs": prevalence, consequences, and implications for policy. Subst Abuse Treat Prev Policy 1: 15.
19. Mache S, Eickenhorst P, Vitzthum K, Klapp BF, Groneberg D (2012) Cognitive-enhancing substance use at German universities: frequency, reasons and gender differences. Wiener Medizinische Wochenschrift 162: 262-271.
20. Franke a G, Lieb K (2010) [Pharmacological neuroenhancement and brain doping: chances and risks]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 53: 853-859.
21. Eickenhorst P, Vitzthum K, Klapp BF, Groneberg D, Mache S (2012) Neuroenhancement among German university students: motives, expectations, and relationship with psychoactive lifestyle drugs. J Psychoactive Drugs 44: 418-427.
22. Dietz P, Striegel H, Franke AG, Lieb K, Simon P, et al. (2013) Randomized response estimates for the 12-month prevalence of cognitive-enhancing drug use in university students. Pharmacotherapy 33: 44-50.
23. Ott R, Lenk C, Miller N, Neuhaus Bühler R, Biller-Andorno N (2012) Neuroenhancement: perspectives of Swiss psychiatrists and general practitioners. Swiss Med Weekly 142: w13707.
24. Repantis D, Schlattmann P, Laisney O, Heuser I (2010) Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 62: 187-206.
25. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, et al. (2003) Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology 165: 260-269. (Pubitemid 36197601)
26. Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, et al. (1997) Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology 131: 196-206. (Pubitemid 27261609)
27. Repantis D (2011) Psychopharmakologische Interventionen für Neuroenhancement bei gesunden Menschen. Berlin: Charité Universitätsmedizin.
28. Wulf MA, Joksimovic L, Tress W (2011) Das Ringen um Sinn und Anerkennung - Eine psychodynamische Sicht auf das Phänomen des Neuroenhancement (NE). Ethik in der Medizin 24: 29-42.
29. Partridge B, Bell S, Lucke J, Hall W (2012) Australian university students' attitudes towards the use of prescription stimulants as cognitive enhancers: perceived patterns of use, efficacy and safety. Drug Alcohol Rev 32: 295-302.
30. Banjo OC, Nadler R, Reiner PB (2010) Physician attitudes towards pharmacological cognitive enhancement: safety concerns are paramount. PLoS One 5: e14322.
31. Franke AG, Lieb K, Hildt E (2012) What users think about the differences between caffeine and illicit/prescription stimulants for cognitive enhancement. PLoS One 7: e40047.
32. Grebner S, Berlowitz I, Alvarado V, Cassina M (2010) Stress bei Schweizer Erwerbstätigen und Gesundheit. Bern: Staatssekretariat für Wirtschaft SECO.
33. Cakic V (2009) Smart drugs for cognitive enhancement: ethical and pragmatic considerations in the era of cosmetic neurology. J Med Ethics 35: 611-615.
34. Kühne R, Rapold R (2011) Der Bezug von Methylphenidat in der Schweiz: Nicht alarmierend - Fragen stellen sich dennoch. Schweizerische Ärztezeitung 92: 1295-1299.
35. Bruggisser M, Bodmer M, Liechti ME (2011) Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets. Swiss Med Weekly 141: w13267.
36. Novak SP, Kroutil LA, Williams RL, Van Brunt DL (2007) The nonmedical use of prescription ADHD medications: results from a national Internet panel. Subst Abuse Treat Prev Policy 2: 32.
37. Ilieva I, Boland J, Farah MJ (2013) Objective and subjective cognitive enhancing effects of mixed amphetamine salts in healthy people. Neuropharmacology 64: 496-505.
38. Quednow BB (2010) Neurophysiologie des Neuro-Enhancements: Möglichkeiten Möglichkeiten und Grenzen. SuchtMagazin 36: 19-26.
39. Gmel G, Kündig H, Maffli E, Notari L, Wicki M, et al. (2012) Suchtmonitoring Schweiz/Jahresbericht - Daten 2011. Bern: Bundesamt für Gesundheit BAG.
40. Franke AG, Schwarze CE, Christmann M, Bonertz C, Hildt E, et al. (2012) [Characteristics of university students using stimulants for cognitive enhancement: a pilot study]. Psychiatr Praxis 39: 174-180.
41. Bruggisser M, Bodmer M, Liechti ME (2012) Methylphenidate misuse. Praxis 101: 299-305.
42. Bell S, Partridge B, Lucke J, Hall W (2013) Australian university students' attitudes towards the acceptability and regulation of pharmaceuticals to improve academic performance. Neuroethics 6: 197-205.
43. Sucht Schweiz (2012) Doping im Alltag. Available at: http://www. suchtschweiz.ch/fileadmin/user-upload/DocUpload/Doping-im-Alltag.pdf. Accessed 2013 Aug 20.